Thomas Kislinger
@kislingerthomas.bsky.social
Senior Scientist at Princess Margaret Cancer Centre, Toronto, Canada 🇨🇦
Clinical proteomics, liquid biopsies and cell surface markers
Clinical proteomics, liquid biopsies and cell surface markers
And in case you missed it, here is her second, equally impressive second preprint.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
Cell surface proteins offer significant cancer therapeutic potential attributable to their accessible membrane localization and central role in cellular signaling. Despite this, their promise remains ...
www.biorxiv.org
September 7, 2025 at 12:55 PM
And in case you missed it, here is her second, equally impressive second preprint.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Interestingly, the urinary proteome of Black patients harboured more features of aggressive cancers than those of grade- and PSA-matched White patients. These observations highlight the importance of controlling for ancestry-associated differences in biomarker development.
August 20, 2025 at 2:08 PM
Interestingly, the urinary proteome of Black patients harboured more features of aggressive cancers than those of grade- and PSA-matched White patients. These observations highlight the importance of controlling for ancestry-associated differences in biomarker development.
This cohort was stratified by ancestry – thought to be a risk-factor for aggressive disease. We found surprisingly large differences and dysregulation of immune pathways.
August 20, 2025 at 2:08 PM
This cohort was stratified by ancestry – thought to be a risk-factor for aggressive disease. We found surprisingly large differences and dysregulation of immune pathways.
After nearly 15 years of urine proteomics of prostate cancer patients, this is our most comprehensive work to date. We generated spectral libraries from hundreds of samples to rapidly analyze 329 post-DRE urines.
August 20, 2025 at 2:08 PM
After nearly 15 years of urine proteomics of prostate cancer patients, this is our most comprehensive work to date. We generated spectral libraries from hundreds of samples to rapidly analyze 329 post-DRE urines.
I am everywhere and nowhere 👻
March 11, 2025 at 9:07 PM
I am everywhere and nowhere 👻
Definitely also expressed in skin.
December 15, 2024 at 7:03 PM
Definitely also expressed in skin.
It gets upregulated in squamous carcinomas and is required for growth and survival
December 15, 2024 at 6:12 PM
It gets upregulated in squamous carcinomas and is required for growth and survival
There is expression in the cerebellum for sure.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
December 15, 2024 at 6:05 PM
There is expression in the cerebellum for sure.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
Might be through that route
Not sure how it gets into milk. Maybe low level expression in some mammary epithelial populations. I will look at our own CSF, urine and normal mammary populations tomorrow.
Actually most datasets correlate reasonable well for Fat2. Since I have worked on this protein for the last 8 years
December 15, 2024 at 5:12 PM
Actually most datasets correlate reasonable well for Fat2. Since I have worked on this protein for the last 8 years
Let us know your thoughts
December 15, 2024 at 3:03 PM
Let us know your thoughts